Business Wire

Andersen Unifies Latin America Platform

25.8.2020 19:00:00 EEST | Business Wire | Press release

Share

The Latin American member firms of Andersen Global will now operate under the brand “Andersen,” reinforcing the organization’s position as a one-stop shop for tax and legal services globally. The announcement comes less than two months after the adoption of the Andersen brand by the European member firms of Andersen Global.

The member firms of Andersen Global in Brazil, Ecuador, Guatemala, Mexico and Uruguay, which previously operated under the brands “Andersen Tax” and “Andersen Tax & Legal,” will now feature Andersen as their brand along with the new member firms, MODO Law and GSRC in Argentina, who became member firms of the organization earlier this year.

Andersen Global continues to view expansion of both its footprint in Latin America and its newly established platform in the Caribbean as high priorities. In Latin America, the global organization also has a presence in Chile, Colombia, Costa Rica, El Salvador, Honduras, Nicaragua, Panama, Paraguay, and Peru through its collaborating firms and has added collaborating firms in 11 countries in the Caribbean region over the last six months.

“Our expansion is driven by client service, and our objective isn’t to be the biggest firm; rather, our focus is about our commitment to building one firm where clients are afforded best-in-class tax and legal services in a seamless fashion across the globe,” Andersen Global Chairman and Andersen CEO Mark Vorsatz said. “Our organization is dedicated not only to our clients, but also to investing in our people and the next generation. We all share the same values and vision regardless of borders and it is only fitting that this is also reflected in our common name.”

The organization’s journey began in 2002, when 23 former Arthur Andersen partners created the tax-only firm WTAS. In 2014, the U.S. member firm proceeded to adopt the brand “Andersen Tax,” and most recently transitioned to the Andersen brand in 2019. The global organization has grown exponentially since the establishment of Andersen Global (formerly WTAS Global) by founding U.S. member firm Andersen Tax LLC in 2013. After launching its global platform in Europe, Andersen Global debuted in Latin America in 2015. The region has since expanded to more than 34 locations, 1,000 tax and legal professionals, and 90 partners today.

Leonardo Mesquita, Regional Managing Director for Latin America added, “Our organization’s foundation is based on our common vision to remain independent and provide seamless, synergistic services to our clients globally. We’re eager to have a brand that reflects what we already know – we are one firm.”

Over the course of the next year, member firms globally will continue to adopt the Andersen brand, while Andersen Global will continue its expansion efforts in critical markets, including the Caribbean, Latin America, Africa and the Middle East.

Andersen Global is an international association of legally separate, independent member firms comprised of tax and legal professionals around the world. Established in 2013 by U.S. member firm Andersen Tax LLC, Andersen Global now has more than 6,000 professionals worldwide and presence in over 191 locations through its member firms and collaborating firms.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Megan Tsuei
Andersen Global
415-764-2700

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye